🇺🇸 FDA
Pipeline program

Autologous Bone Marrow-derived Mononuclear Cells

13-006427

Phase 1 mab completed

Quick answer

Autologous Bone Marrow-derived Mononuclear Cells for Congenital Heart Disease is a Phase 1 program (mab) at Regen BioPharma Inc with 1 ClinicalTrials.gov record(s).

Program details

Company
Regen BioPharma Inc
Indication
Congenital Heart Disease
Phase
Phase 1
Modality
mab
Status
completed

Clinical trials